Viral Vectors and Plasmid DNA Manufacturing Market Size to Hit USD 29.82 Bn by 2035

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Vector Type

7.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Vector Type,

7.1.1. Adenovirus

7.1.1.1. Market Revenue and Forecast

7.1.2. Plasmid DNA

7.1.2.1. Market Revenue and Forecast

7.1.3. Lentivirus

7.1.3.1. Market Revenue and Forecast

7.1.4. Retrovirus

7.1.4.1. Market Revenue and Forecast

7.1.5. AAV

7.1.5.1. Market Revenue and Forecast

7.1.6. Others

7.1.6.1. Market Revenue and Forecast

Chapter 8. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Application Type

8.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Application Type,

8.1.1. Gene Therapy

8.1.1.1. Market Revenue and Forecast

8.1.2. Antisense &RNAi

8.1.2.1. Market Revenue and Forecast

8.1.3. Cell Therapy

8.1.3.1. Market Revenue and Forecast

8.1.4. Vaccinology

8.1.4.1. Market Revenue and Forecast

Chapter 9. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Workflow Type

9.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Workflow Type,

9.1.1. Upstream Processing (Vector Recovery/Harvesting, Vector Amplification & Expansion)

9.1.1.1. Market Revenue and Forecast

9.1.2. Downstream Processing (Fill-finish, Purification)

9.1.2.1. Market Revenue and Forecast

Chapter 10. Global Viral Vectors & Plasmid DNA Manufacturing Market, By End-User Type

10.1. Viral Vectors & Plasmid DNA Manufacturing Market, by End-User Type,

10.1.1. Biopharmaceutical and Pharmaceutical Companies

10.1.1.1. Market Revenue and Forecast

10.1.2. Research Institutes

10.1.2.1. Market Revenue and Forecast

Chapter 11. Global Viral Vectors & Plasmid DNA Manufacturing Market, By Disease

11.1. Viral Vectors & Plasmid DNA Manufacturing Market, by Disease,

11.1.1. Genetic Disorders

11.1.1.1. Market Revenue and Forecast

11.1.2. Cancer

11.1.2.1. Market Revenue and Forecast

11.1.3. Infectious Diseases

11.1.3.1. Market Revenue and Forecast

11.1.4. Others

11.1.4.1. Market Revenue and Forecast

Chapter 12. Global Viral Vectors & Plasmid DNA Manufacturing Market, Regional Estimates and Trend Forecast

12.1. North America

12.1.1. Market Revenue and Forecast, by Vector

12.1.2. Market Revenue and Forecast, by Application

12.1.3. Market Revenue and Forecast, by Workflow

12.1.4. Market Revenue and Forecast, by End-User

12.1.5. Market Revenue and Forecast, by Disease

12.1.6. U.S.

12.1.6.1. Market Revenue and Forecast, by Vector

12.1.6.2. Market Revenue and Forecast, by Application

12.1.6.3. Market Revenue and Forecast, by Workflow

12.1.6.4. Market Revenue and Forecast, by End-User

12.1.7. Market Revenue and Forecast, by Disease

12.1.8. Rest of North America

12.1.8.1. Market Revenue and Forecast, by Vector

12.1.8.2. Market Revenue and Forecast, by Application

12.1.8.3. Market Revenue and Forecast, by Workflow

12.1.8.4. Market Revenue and Forecast, by End-User

12.1.9. Market Revenue and Forecast, by Disease

12.2. Europe

12.2.1. Market Revenue and Forecast, by Vector

12.2.2. Market Revenue and Forecast, by Application

12.2.3. Market Revenue and Forecast, by Workflow

12.2.4. Market Revenue and Forecast, by End-User

12.2.5. Market Revenue and Forecast, by Disease

12.2.6. UK

12.2.6.1. Market Revenue and Forecast, by Vector

12.2.6.2. Market Revenue and Forecast, by Application

12.2.6.3. Market Revenue and Forecast, by Workflow

12.2.7. Market Revenue and Forecast, by End-User

12.2.8. Market Revenue and Forecast, by Disease

12.2.8.1. Market Revenue and Forecast, by Raw Material

12.2.9. Germany

12.2.9.1. Market Revenue and Forecast, by Vector

12.2.9.2. Market Revenue and Forecast, by Application

12.2.9.3. Market Revenue and Forecast, by Workflow

12.2.10. Market Revenue and Forecast, by End-User

12.2.11. Market Revenue and Forecast, by Disease

12.2.12. France

12.2.12.1. Market Revenue and Forecast, by Vector

12.2.12.2. Market Revenue and Forecast, by Application

12.2.12.3. Market Revenue and Forecast, by Workflow

12.2.12.4. Market Revenue and Forecast, by End-User

12.2.13. Market Revenue and Forecast, by Disease

12.2.14. Rest of Europe

12.2.14.1. Market Revenue and Forecast, by Vector

12.2.14.2. Market Revenue and Forecast, by Application

12.2.14.3. Market Revenue and Forecast, by Workflow

12.2.14.4. Market Revenue and Forecast, by End-User

12.2.15. Market Revenue and Forecast, by Disease

12.3. APAC

12.3.1. Market Revenue and Forecast, by Vector

12.3.2. Market Revenue and Forecast, by Application

12.3.3. Market Revenue and Forecast, by Workflow

12.3.4. Market Revenue and Forecast, by End-User

12.3.5. Market Revenue and Forecast, by Disease

12.3.6. India

12.3.6.1. Market Revenue and Forecast, by Vector

12.3.6.2. Market Revenue and Forecast, by Application

12.3.6.3. Market Revenue and Forecast, by Workflow

12.3.6.4. Market Revenue and Forecast, by End-User

12.3.7. Market Revenue and Forecast, by Disease

12.3.8. China

12.3.8.1. Market Revenue and Forecast, by Vector

12.3.8.2. Market Revenue and Forecast, by Application

12.3.8.3. Market Revenue and Forecast, by Workflow

12.3.8.4. Market Revenue and Forecast, by End-User

12.3.9. Market Revenue and Forecast, by Disease

12.3.10. Japan

12.3.10.1. Market Revenue and Forecast, by Vector

12.3.10.2. Market Revenue and Forecast, by Application

12.3.10.3. Market Revenue and Forecast, by Workflow

12.3.10.4. Market Revenue and Forecast, by End-User

12.3.10.5. Market Revenue and Forecast, by Disease

12.3.11. Rest of APAC

12.3.11.1. Market Revenue and Forecast, by Vector

12.3.11.2. Market Revenue and Forecast, by Application

12.3.11.3. Market Revenue and Forecast, by Workflow

12.3.11.4. Market Revenue and Forecast, by End-User

12.3.11.5. Market Revenue and Forecast, by Disease

12.4. MEA

12.4.1. Market Revenue and Forecast, by Vector

12.4.2. Market Revenue and Forecast, by Application

12.4.3. Market Revenue and Forecast, by Workflow

12.4.4. Market Revenue and Forecast, by End-User

12.4.5. Market Revenue and Forecast, by Disease

12.4.6. GCC

12.4.6.1. Market Revenue and Forecast, by Vector

12.4.6.2. Market Revenue and Forecast, by Application

12.4.6.3. Market Revenue and Forecast, by Workflow

12.4.6.4. Market Revenue and Forecast, by End-User

12.4.7. Market Revenue and Forecast, by Disease

12.4.8. North Africa

12.4.8.1. Market Revenue and Forecast, by Vector

12.4.8.2. Market Revenue and Forecast, by Application

12.4.8.3. Market Revenue and Forecast, by Workflow

12.4.8.4. Market Revenue and Forecast, by End-User

12.4.9. Market Revenue and Forecast, by Disease

12.4.10. South Africa

12.4.10.1. Market Revenue and Forecast, by Vector

12.4.10.2. Market Revenue and Forecast, by Application

12.4.10.3. Market Revenue and Forecast, by Workflow

12.4.10.4. Market Revenue and Forecast, by End-User

12.4.10.5. Market Revenue and Forecast, by Disease

12.4.11. Rest of MEA

12.4.11.1. Market Revenue and Forecast, by Vector

12.4.11.2. Market Revenue and Forecast, by Application

12.4.11.3. Market Revenue and Forecast, by Workflow

12.4.11.4. Market Revenue and Forecast, by End-User

12.4.11.5. Market Revenue and Forecast, by Disease

12.5. Latin America

12.5.1. Market Revenue and Forecast, by Vector

12.5.2. Market Revenue and Forecast, by Application

12.5.3. Market Revenue and Forecast, by Workflow

12.5.4. Market Revenue and Forecast, by End-User

12.5.5. Market Revenue and Forecast, by Disease

12.5.6. Brazil

12.5.6.1. Market Revenue and Forecast, by Vector

12.5.6.2. Market Revenue and Forecast, by Application

12.5.6.3. Market Revenue and Forecast, by Workflow

12.5.6.4. Market Revenue and Forecast, by End-User

12.5.7. Market Revenue and Forecast, by Disease

12.5.8. Rest of LATAM

12.5.8.1. Market Revenue and Forecast, by Vector

12.5.8.2. Market Revenue and Forecast, by Application

12.5.8.3. Market Revenue and Forecast, by Workflow

12.5.8.4. Market Revenue and Forecast, by End-User

12.5.8.5. Market Revenue and Forecast, by Disease

Chapter 13. Company Profiles

13.1. Novasep

13.1.1. Company Overview

13.1.2. Product Offerings

13.1.3. Financial Performance

13.1.4. Recent Initiatives

13.2. Aldevron

13.2.1. Company Overview

13.2.2. Product Offerings

13.2.3. Financial Performance

13.2.4. Recent Initiatives

13.3. Merck Waisman Biomanufacturing

13.3.1. Company Overview

13.3.2. Product Offerings

13.3.3. Financial Performance

13.3.4. Recent Initiatives

13.4. Creative Biogene

13.4.1. Company Overview

13.4.2. Product Offerings

13.4.3. Financial Performance

13.4.4. Recent Initiatives

13.5. The Cell and Gene Therapy Catapult

13.5.1. Company Overview

13.5.2. Product Offerings

13.5.3. Financial Performance

13.5.4. Recent Initiatives

13.6. Cobra Biologics

13.6.1. Company Overview

13.6.2. Product Offerings

13.6.3. Financial Performance

13.6.4. Recent Initiatives

13.7. uniQure N.V.

13.7.1. Company Overview

13.7.2. Product Offerings

13.7.3. Financial Performance

13.7.4. Recent Initiatives

13.8. Addgene

13.8.1. Company Overview

13.8.2. Product Offerings

13.8.3. Financial Performance

13.8.4. Recent Initiatives

13.9. FUJIFILM Holdings Corporation

13.9.1. Company Overview

13.9.2. Product Offerings

13.9.3. Financial Performance

13.9.4. Recent Initiatives

13.10. Oxford Biomedicaplc

13.10.1. Company Overview

13.10.2. Product Offerings

13.10.3. Financial Performance

13.10.4. Recent Initiatives

13.11. Takara Bio Inc.

13.11.1. Company Overview

13.11.2. Product Offerings

13.11.3. Financial Performance

13.11.4. Recent Initiatives

Chapter 14. Research Methodology

14.1. Primary Research

14.2. Secondary Research

14.3. Assumptions

Chapter 15. Appendix

15.1. About Us

15.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

Answer : The global viral vectors & plasmid DNA manufacturing market was estimated at USD 7.26 billion in 2025 and is expected to reach USD 29.82 billion by 2035.

Answer : The global viral vectors & plasmid DNA manufacturing market is growing at a CAGR of 15.17% from 2026 to 2035.

Answer : Growing occurrence of target disorders and diseases and efficiency of viral vectors in gene therapy delivery are driving the growth of viral vectors & plasmid DNA manufacturing market.

Answer : The driving factors of the viral vectors & plasmid DNA manufacturing market is the increasing adoption of gene therapies for rare and genetic diseases.

Answer : Viral vectors have become ideal choice for gene transferdue to their efficient gene delivery, high transfection efficiency and stable gene expression. Further, upsurge in registration of clinical trials on viral vector-mediated gene therapy is stimulating inclination for viral vectors in gene transfer.